33 results about "Carcinoma" patented technology

The invention discloses a hepatocellular carcinoma postoperative early recurrence prediction method based on multi-modal fusion. The method comprises the following steps: firstly, integrating clinical data of a training set, a preoperative enhanced CT image and a postoperative full-view digital pathological image, and carrying out standardized correction; then, traditional image omics features and deep learning features are extracted from the CT image, cell nucleus morphological features and tumor microenvironment spatial configuration features are extracted from the pathological image, and key feature signatures are screened out through a maximum correlation minimum redundancy algorithm (mRMR) and LASSO regression in combination with clinical features. And then carrying out progressive model construction by adopting an XGBoost algorithm, sequentially establishing a clinical single-mode model, an image single-mode model, a pathological single-mode model and a multi-mode fusion model, and explaining and visualizing the models by utilizing an SHAP value and a Grad-CAM technology. Finally, the performance of the model is evaluated in a multi-dimensional mode through internal cross validation, foresight and external independent validation, risk layering is carried out based on the prediction probability, and individualized postoperative management is guided.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

The utility model discloses a portable sampling device for endometrial cancer gene methylation detection in the technical field of sampling devices, which comprises an extraction cylinder, one end of the extraction cylinder is fixedly inserted with a connecting pipe, the inner wall of the connecting pipe is movably inserted with a detachable extraction pipe, and the inner wall of the detachable extraction pipe is movably inserted with a connecting pipe. A plurality of guide blocks are fixedly arranged on the outer wall of the end, inserted into the connecting pipe, of the detachable extraction pipe, the guide blocks are in sliding fit with the inner wall of the connecting pipe, and two toothed plate sealing pieces used for blocking the connecting pipe are movably arranged on the inner wall of the extraction cylinder; after the device is used, the grab handle is firstly detached, then the detachable extraction pipe is detached, and at the moment, the guide block slides along the inner wall of the connecting pipe, so that the connecting pipe drives the transmission gear to rotate reversely, and the two toothed plate sealing pieces are reset along with the reverse rotation of the transmission gear to seal the connecting pipe; therefore, the possibility that external sundries enter the extraction barrel through the connecting pipe when the device is not used is reduced.

A method of treating cancer involves administering a combination of activators comprising a therapeutically effective dose of acylfluben or a pharmaceutically acceptable salt thereof and a therapeutically effective dose of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tocitumomab. The cancer may be a B-cell carcinoma.

The invention relates to the technical field of diagnosis, in particular to a prognosis evaluation kit and evaluation method for renal cell carcinoma patients based on DNAJA1 protein expression quantity. The method for evaluating the prognosis and immune microenvironment state of the RCC patient based on the DNAJA1 expression level provided by the invention has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

Proposed are a sessile droplet biosensor and an extracellular vesicle detection method using same, wherein the sessile droplet biosensor can easily and conveniently perform superbright staining of proteins or lipids in extracellular vesicles through a non-specific staining material, such as CFSE, without a complicated signal generation process and can concentrate extracellular vesicles to a high concentration at the edges of sessile droplets by internal flowing induced by non-uniform evaporation in the sessile droplets, thereby detecting extracellular vesicles with high sensitivity. Moreover, the extracellular vesicle detection method using the sessile droplet biosensor can be utilized for standard setting technology for various diseases, such as cancer diagnosis standard setting technology, by the analysis of extracellular vesicle staining signals, or an information providing method for the analysis of extracellular vesicle staining signals can be utilized for early diagnosis of various diseases such as cancer, evaluation of prognosis for treatment, and screening for carcinoma.

The compositions provided herein including embodiments thereof include, inter alia, TGF-beta-binding agents that bind to TGF-beta in its active / mature form (i.e., active TGF-beta, mature TGF-beta). Further provided are methods of treatment including, inter alia, administering to a patient a diagnostic and a therapeutic TGF-beta-binding agents both including a radioisotope. The compositions and methods provided herein are, inter alia, useful as theranostics for the treatment of cancer (e.g., solid tumors such as carcinoma or sarcoma).

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.

A method of treating cancer cells includes contacting the cancer cells with a CoO / CaSiO3@g-C3N4 nanocomposite material. The CoO / CaSiO3@g-C3N4 nanocomposite material includes hexagonal metal oxide nanoparticles comprising a CoO phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets. The hexagonal metal oxide nanoparticles have an average particle diameter in a range from 340 to 440 nm. The CoO / CaSiO3@g-C3N4 nanocomposite material has a percent inhibition for Human Breast Carcinoma (MCF-7) cells at least 55% inhibition in an in-vitro cellular viability assay.

The application discloses application of an HTRA1 inhibitor in preparation of a drug for treating pancreatitis-cancer transformation, and belongs to the technical field of medicines.The HTRA1 inhibitor is screened through a drug database, the HTRA1 inhibitor is used to treat a pancreatic cancer cell line and a mouse pancreatitis-cancer transformation in-vivo model, it is proved that the HTRA1 inhibitor Carfilzomib can inhibit the malignant phenotype of Panc1 cells in vitro, and can inhibit the transformation of a KC mouse stimulated by cerulean into a pancreatic ductal adenocarcinoma in vivo, and the application provides a basis for using the HTRA1 inhibitor as the drug for treating pancreatitis-cancer transformation.

This invention discloses a high-performance computing-based system and method for evaluating colorectal cancer screening strategies, belonging to the field of medical information processing technology. It includes: a dual-pathway disease model module supporting both adenoma-carcinoma pathways and serrated adenoma pathways, modeled using age-dependent normal distribution progression time; an individualized risk scoring module integrating risk factors such as family history, inflammatory bowel disease, obesity, and diabetes; a screening strategy simulation module supporting combined screening strategies using different tools, employing compliance parameters specific to the Chinese urban population; a high-performance computing module using Numba JIT compilation technology for acceleration, multi-process parallel processing for further acceleration, and data structure optimization such as integer age to reduce memory usage; and a health economics evaluation module calculating indicators such as QALY, LYG, and ICER. This invention achieves significant performance improvements while maintaining model accuracy, greatly reducing simulation time for large-scale populations.

The present disclosure provides a targeted B7-H3 single-domain antibody, a chimeric antigen receptor molecule, a chimeric antigen receptor cell, and their application in the preparation of drugs for treating nasopharyngeal carcinoma, which belongs to the field of antibody drug technology; an amino acid sequence of the B7-H3 targeted single-domain antibody provided by the present disclosure is shown in SEQ ID No. 1, and an amino acid sequence of the chimeric antigen receptor molecule is shown in SEQ ID No. 2; the chimeric antigen receptor cell provided by the present disclosure can specifically bind to tumor cells through targeting B7-H3 and exert specific antitumor effects via antigen-dependent mechanism, making it one of the potential effective methods for treating recurrent and metastatic NPC; according to the records of the embodiments, after co-culturing the chimeric antigen receptor cell provided by the present disclosure with the nasopharyngeal carcinoma cell line HK1-EBV, it can significantly kill nasopharyngeal carcinoma cell.

The present invention provides an in vitro method for detecting immuno-suppressive fibroblasts, in particular cancer-associated fibroblasts (CAFs), in a cancerous sample from a subject suffering from a carcinoma, the method comprising detecting ANTXR1 + fibroblasts in a cancerous sample from this patient.SOLUTION: The present invention also relates to an in vitro method for predicting the response of a subject suffering from cancers to an immunotherapeutic treatment, an immunotherapeutic treatment for use in treating cancers in patients, the use of ANTXR1 as a biomarker for the identification of immunosuppressive fibroblasts, in particular immunosuppressive CAFs, an agent targeting ANTXR1 + fibroblasts for use in treating cancers in patients, an article of manufacture or a kit comprising a) an agent targeting ANTXR1 + fibroblasts and b) an immunotherapeutic treatment.SELECTED DRAWING: None

To provide an antibody specifically binding to Axl protein, an immunoconjugate and a pharmaceutical composition.SOLUTION: Provided are single-chain antigen-binding antibodies that specifically bind to Axl proteins, comprising a heavy chain variable region and a light chain variable region having specific amino acid sequences, wherein all of the amino acid sequence mutations to the specific amino acid sequences occur only in the framework regions, and wherein the antibodies have higher binding affinities to Axl proteins at a pH of a tumor microenvironment ranging from pH7. 8 to 7.0 compared to a non-tumor microenvironment ranging from pH5. 2 to 7.6. Also provided is an immunoconjugate comprising the single-chain antigen-binding antibody, a linker molecule, and one or more cytotoxic agents covalently attached to the single-chain antigen-binding antibody and the linker molecule. Further provided is a pharmaceutical composition comprising said single-chain antigen-binding antibody for use as a medicament for the treatment of carcinoma.SELECTED DRAWING: None

The invention discloses an AI auxiliary remote consultation system for testicular nucleoprotein carcinoma, and relates to the technical field of medical information, and the system comprises a multi-modal data fusion processing module which is used for receiving and preprocessing patient multi-modal medical data from different medical institutions; the dynamic feature extraction and tumor evolution modeling module is used for extracting dynamic pathological features related to the testicular nucleoprotein cancer from the fused multi-dimensional feature tensor; the core of the expert diagnosis logic deep simulation module is a deep reinforcement learning network which is pre-trained and continuously learns online; and the real-time interaction and decision synchronization module is used for coordinating data streams and control signals among the modules in the system and managing real-time communication with a remote terminal user. The system solves the problems that an existing system is insufficient in testicular nucleoprotein cancer multi-modal data fusion capability, poor in rare case generalization and low in real-time decision-making efficiency, and the diagnosis accuracy and the remote cooperation efficiency are improved.

The disclosure belongs to the field of microorganisms, and in particular relates to a strain of Akkermansia muciniphila and a product and application thereof. The A. muciniphila is AKK PROBIO, with a preservation number of CGMCC No. 20955. AKK PROBIO of the disclosure has good tolerance, high safety, wide indications, and a good therapeutic effect, can prevent and treat diseases such as colitis, colorectal carcinoma, Alzheimer's disease, and gouty arthritis, and has very good clinical application prospects.

The invention provides a marker and a kit for distinguishing breast cancer tissues from para-carcinoma normal tissues in a breast cancer patient and application of the marker and the kit. The marker is taurine, threonic acid and / or glutamic acid. According to the invention, a multi-modal imaging technology is combined with an XGBoost model to construct a taurine, threonic acid and glutamic acid three-marker combined identification model, and the accuracy of the model is as high as 0.985 (95% CI: 0.963, 1.000). Further analysis finds that the taurine content is gradually reduced from the tumor center to the infiltration edge, and the taurine can be used as a biomarker for distinguishing breast cancer and paracancerous normal tissues.

The present invention relates to: an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 or an antigen-binding fragment thereof; and a pharmaceutical composition for treating cancer, comprising same as an active ingredient. The antibody-drug conjugate of the present invention comprises an antibody specifically targeting GRP94 and having strong internalization activity, and, as a result of conjugation with a cytotoxic agent, effectively inhibits the growth of cetuximab-resistant CRC cell lines including HT29, HCT116, HCT8 and LoVo cells, and thus can be effectively used as a therapeutic agent for various carcinomas in which GRP94 is overexpressed.

The invention discloses a long-term follow-up visit system after esophageal-gastric junction adenocarcinoma resection, and relates to the technical field related to hospital information management, and the long-term follow-up visit system comprises a multi-modal data acquisition layer which is used for obtaining medical data from a hospital information system; the wearable device collects physiological indexes; and an embedded electrochemical sensor, an air quality monitor, a water quality analyzer and an electromagnetic radiation dosimeter. The intelligent data processing layer is used for analyzing CT and PET images by adopting a 3D convolutional neural network, carrying out unstructured data processing and extracting tumor metabolism characteristics; fusing the physiological indexes and the environmental data by using an LSTM network, carrying out time sequence data analysis, and constructing a dynamic health index; environment exposure index modeling is carried out, and a pollutant exposure index is calculated. Clinical data, environmental data, behavior data and gene data are covered through the multi-modal data acquisition layer, multi-dimensional information fusion is realized, the one-sidedness that traditional follow-up visit depends on a single index is solved, and a comprehensive data basis is provided for accurate prediction.

The invention discloses a urinary tract epithelial cancer detection reagent, a detection kit and application thereof. Specifically, the invention provides application of the reagent combination in preparation of the kit, and the reagent combination comprises a reagent for detecting the methylation level or state of a CpG island region comprising the following genes in a sample to be detected: (A) the CpG island region of the DMRTA2 gene is located in a chr1: 50421000-50421550 region; and (B) a CpG island region of any one gene selected from the following groups, or a combination thereof: (B1) the CpG island region of the TWIST1 gene is located in the chr7: 19117550-19118050 region; and (B2) the CpG island region of the VIM gene is located in the chr10: 17229200-17229700 region. The reagent or the kit provided by the invention can realize rapid and high-sensitivity non-invasive detection.

The invention relates to the technical field of nutritious sports food, and discloses cashew nut and sea cucumber peptide exercise recovery powder and a method, the cashew nut and sea cucumber peptide exercise recovery powder comprises the following components by mass: 40%-55% of a composite peptide composition, 25%-35% of a rapid energy supply matrix, 5%-10% of an anti-inflammatory active component, and 10%-15% of a synergistic auxiliary agent, the composite peptide composition is formed by compounding a cashew nut extract and sea cucumber peptide according to a mass ratio of (4-6): (3-5), the molecular weight distribution of the cashew nut extract is 200-800Da, the purity of the cashew nut extract is greater than or equal to 92%, the molecular weight distribution of the sea cucumber peptide is 300-1000Da, the purity of the sea cucumber peptide is greater than or equal to 90%, the rapid energy supply matrix is formed by compounding maltodextrin and fructo-oligosaccharide according to a mass ratio of (3-4): 1, and the anti-inflammatory active component comprises curcumin microcapsules and resveratrol. Through the specific compounding design of the cashew nut extract and the sea cucumber peptide, in combination with precise molecular weight control, advantage complementation of amino acid composition is achieved, and the gastrointestinal tract absorption efficiency of nutritional ingredients is remarkably improved in cooperation with a targeted slow release technology of curcumin microcapsules.

The present invention relates to a fusion protein that specifically binds to the extradomain B of fibronectin (EDB-FN) and transforming growth factor β (TGF-β), and use thereof; and, more specifically, to a fusion protein comprising a polypeptide that specifically binds to EDB-FN and a polypeptide that specifically binds to TGF-β, and use thereof.The fusion protein according to the present invention fixes TGF-β, which plays an important role in antitumor immune responses, to the extracellular matrix, in order to localize the inhibition of TGF-β directly in the tumor microenvironment and ensure a local rather than systemic effect, thus showing an excellent anticancer effect in all carcinomas, including pancreatic cancer, in which the usual TGF-β inhibitors do not act due to the rigidity of the extracellular matrix, so that it can be used effectively for the prevention or treatment of cancer.

The present invention relates to the adaptation and modification of Coxsackievirus B3 (CVB3) and their use or the use of their genomic RNA for the treatment of cancer, in particular for the treatment of gastrointestinal cancer, and furthermore particularly pancreatic and colorectal carcinomas.

The utility model relates to the technical field of esophageal cancer detection kits, in particular to a pressing type esophageal cancer detection kit which comprises a kit body, a kit cover is arranged at the front end of the kit body, a placing frame is arranged in the kit body, and a plurality of sets of inserting grooves are formed in the placing frame in an array mode. A plurality of sets of first movable grooves are formed in the lower end of the containing frame in an array mode, and springs are installed in the multiple sets of first movable grooves. A reagent bottle containing a substance to be detected is placed in the device placing frame, then two groups of baffles are inserted between two groups of connecting rods in a sliding manner, and then the two groups of connecting rods and the two groups of baffles slide into four groups of second movable grooves through four groups of second movable rods and apply pressure downwards, so that the substance to be detected is detected. The two groups of connecting rods and the two groups of baffles slide downwards and press the reagent bottles inserted into the multiple groups of first movable grooves downwards, and the reagent bottles are tightly attached to the interiors of the multiple groups of baffles under the action of resilience force of the multiple groups of springs and the multiple groups of first movable rods.

The present invention relates anti-microbial antibody signatures related to lung tumors, including benign tumors and adenocarcinomas. Disclosed herein are antibody panels comprising antigens from bacteria and / or viruses for use in early and accurate diagnosis of lung cancer and for reducing false positive lung carcinoma diagnoses from CT screening.

Provided herein are compositions comprising a multispecific (e.g., bispecific) antibody, e.g., an Alkalitumab, that binds to CD3 and BCMA, and methods of using such compositions to treat patients suffering from a disorder associated with the expression of BCMA (e.g., BCMA-expressing B-cell carcinoma, e.g., multiple myeloma).

The present disclosure describes cyclic peptide modulators of Factor XII(FXII) -uPAR signalling. Also described are pharmaceutical compositions comprising the cyclic peptides and their use in treating conditions, diseases and / or disorders responsive to FXII-uPAR modulation, including carcinoma, ovarian cancer, venous thromboembolisms and wound healing.

The present invention relates to pharmaceutical compositions and methods for the treatment of carcinomas and sarcomas. In particular, the invention provides a pharmaceutical composition comprising a peptide or pharmaceutically acceptable salt thereof for use in treating a carcinoma or a sarcoma in a human subject, wherein the peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1 and a cell penetrating peptide and wherein the pharmaceutical composition is systemically administered to the subject weekly to provide a dose of the peptide of about 15-65 mg / m2 body surface area (BSA) per week, calculated as the free form of the peptide.